PDSB - PDS Biotechnology Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Florham Park,
United States
Type: Equity
PDSB price evolution
PDSB
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $57.73 | $66.63 | $56.56 | |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $52.13 | $60.16 | $68.69 | $59.06 |
| Long term investments | ||||
| Property, plant & equipment | $0.32 | $0.33 | $0.32 | $0.34 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.33 | $0.32 | $0.34 | |
| Total investments | ||||
| Total assets | $52.45 | $60.5 | $69.01 | $59.39 |
| Current liabilities | ||||
| Accounts payable | $1.3 | $3.25 | $6 | $6.98 |
| Deferred revenue | ||||
| Short long term debt | $10.48 | $7.35 | $4.22 | |
| Total current liabilities | $18.34 | $15.67 | $15.06 | $13.63 |
| Long term debt | $12.11 | $13.9 | $16.76 | $19.63 |
| Total noncurrent liabilities | $13.9 | $16.76 | $19.63 | |
| Total debt | $24.38 | $24.11 | $23.85 | |
| Total liabilities | $30.45 | $29.58 | $31.82 | $33.26 |
| Shareholders' equity | ||||
| Retained earnings | -$174.16 | -$163.43 | -$155.1 | -$144.5 |
| Other shareholder equity | ||||
| Total shareholder equity | $30.92 | $37.18 | $26.13 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $56.56 | $73.82 | $65.24 | $28.84 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $59.06 | $76.48 | $66.84 | $30.34 |
| Long term investments | ||||
| Property, plant & equipment | $0.34 | $0.53 | $0.36 | $0.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.34 | $0.53 | $0.36 | $0.55 |
| Total investments | ||||
| Total assets | $59.39 | $77.01 | $67.2 | $30.89 |
| Current liabilities | ||||
| Accounts payable | $6.98 | $1.22 | $1.31 | $1.42 |
| Deferred revenue | ||||
| Short long term debt | $4.22 | $0.29 | $0.26 | $0.12 |
| Total current liabilities | $13.63 | $9.82 | $3.76 | $3.27 |
| Long term debt | $19.63 | $23.18 | $0.23 | $0.49 |
| Total noncurrent liabilities | $19.63 | $23.18 | $0.23 | $0.49 |
| Total debt | $23.85 | $23.47 | $0.49 | $0.61 |
| Total liabilities | $33.26 | $33.01 | $3.99 | $3.76 |
| Shareholders' equity | ||||
| Retained earnings | -$144.5 | -$101.56 | -$60.7 | -$43.79 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | $26.13 | $44 | $63.21 | $27.13 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $4.53 | $6.7 | $7.47 | |
| Selling, general & administrative | $4.16 | $3.39 | $2.94 | |
| Total operating expenses | $10.18 | $8.68 | $10.1 | $10.41 |
| Operating income | -$8.68 | -$10.1 | -$10.41 | |
| Income from continuing operations | ||||
| EBIT | -$8.68 | -$10.1 | -$10.41 | |
| Income tax expense | -$0.87 | $0 | ||
| Interest expense | -$0.55 | $0.51 | $0.51 | $0.49 |
| Net income | ||||
| Net income | -$10.73 | -$8.33 | -$10.6 | -$10.9 |
| Income (for common shares) | -$8.33 | -$10.6 | -$10.9 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $27.76 | $29.43 | $11.25 | $7.92 |
| Selling, general & administrative | $15.28 | $12.24 | $10.18 | $6.96 |
| Total operating expenses | $43.05 | $41.67 | $21.44 | $14.9 |
| Operating income | -$43.05 | -$41.67 | -$21.44 | -$14.9 |
| Income from continuing operations | ||||
| EBIT | -$43.05 | -$41.67 | -$21.43 | -$14.85 |
| Income tax expense | -$1.41 | -$1.2 | -$4.52 | |
| Interest expense | $1.3 | $0.38 | ||
| Net income | ||||
| Net income | -$42.94 | -$40.85 | -$16.92 | -$14.85 |
| Income (for common shares) | -$42.94 | -$40.85 | -$16.92 | -$14.85 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$8.33 | -$10.6 | -$10.9 | |
| Operating activities | ||||
| Depreciation | $0.02 | $0.01 | -$0.03 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.8 | $1.63 | $1.35 | |
| Total cash flows from operations | -$8.86 | -$9.94 | -$8.46 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.03 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $20.03 | $10.78 | ||
| Net borrowings | -$0.01 | -$0.01 | -$0.01 | |
| Total cash flows from financing | $20.02 | -$0.01 | $20.01 | $10.77 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$6.81 | -$8.9 | $10.07 | $2.31 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$42.94 | -$40.85 | -$16.92 | -$14.85 |
| Operating activities | ||||
| Depreciation | $0.18 | $0.24 | $0.25 | $0.18 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.61 | $5.2 | $4.07 | $0.43 |
| Total cash flows from operations | -$33.64 | -$25.71 | -$12.49 | -$13.15 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $16.44 | $10.01 | $48.89 | $29.83 |
| Net borrowings | -$0.06 | $24.55 | ||
| Total cash flows from financing | $16.38 | $34.29 | $48.89 | $29.83 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$17.26 | $8.58 | $36.4 | $16.68 |
News
Fundamentals
| Market cap | $51.92M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 36.82M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$40.56M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -1.28 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.10 |
|---|---|
| ROA | -67.22% |
| ROE | N/A |
| Debt/Equity | 1.27 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.84 |
| Quick ratio | N/A |